[27P2-pm2] Clinical Pharmacy 3

[27P2-pm2-096] Development of a novel TKI derivative for enhancing the anticancer potential of 5-aminolevulinic acid-based photodynamic therapy

○Yoshio Endo¹, Yoshihiro Uto², Yusei Shinohara³, Chiaki Abe⁴, Tohru Obata⁵, Shun-ichiro Ogura⁶, Yutaka Yonemura⁷ (1. Cancer Res. Inst., Kanazawa Univ., 2. Grad. Sch. Tech., Ind. Soc. Sci., Tokushima Univ., 3. Grad. Sch. Adv. Tech. Sci., Tokushima Univ., 4. Grad. Sch. of Med., Kyoto Univ., 5. Sch. Pharm., Aichi Gakuin Univ., 6. Grad. Sch. Biosci. Biotech., Tokyo Tech., 7. NPO Org. support Peritoneal Dissemination Treat.)